A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

The experimental mRNA-based drug sharply reduced the risk of recurrence or death when combined with immunotherapy Keytruda, ...

Biocon recently unveiled three new biosimilar oncology assets to its R&D pipeline —trastuzumab/hyaluronidase (Herceptin SC/Herceptin Hylecta), nivolumab (Opdivo) and pembrolizumab (Keytruda).

The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...

The FDA approved adjuvant Keytruda for patients ages 12 and older with stage 2b, 2c or 3 melanoma that has been completely resected. The Food and Drug Administration (FDA) approved adjuvant Keytruda ...

Patients with severe melanoma who received the treatment were 49% less likely to die or have their cancer return, ...

Applications based on Phase 3 KEYNOTE-905 results showing the combination improved event-free survival by 60%, reduced the risk of death by 50% and increased pathologic complete response rates by 48% ...

Merck MRK announced that the FDA has approved both the intravenous (“IV”) and the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), each in ...

A meaningful portion of Merck’s MRK revenues comes from its oncology franchise anchored by its blockbuster PD-L1 inhibitor, ...

Keytruda Qlex must be administered by a health care provider. The Food and Drug Administration (FDA) has approved Keytruda Qlex ™ (pembrolizumab and berahyaluronidase alfa-pmph) for patients aged 12 ...